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Summary Of a total of 307 patients treated with chemotherapy for advanced non-seminomatous germ-cell
testicular tumours between 1976 and 1983, 73 (23.8%) had masses excised after treatment. Resected tissue
showed residual malignancy in 16 (22%), fibrosis and necrosis in 25 (34%) and differentiated (mature
teratoma) in 32 (44%). Of the 16 patients with tumour only 7 (44%) are alive and disease-free compared with
21/25 (84%) and 27/32 (84%) for fibrosis/necrosis and differentiated teratoma respectively. In addition to
histological evidence of residual tumour, elevated serum markers at the time of surgery and/or incomplete
excision of residual masses were adverse prognostic features. Of 12 patients with differentiated teratoma or
fibrosis who had incomplete resections or densely adherent masses excised with difficulty, 7 subsequently
relapsed.
The majority of differentiated teratoma patients (75%) had evidence of differentiation in their primary
tumours; 88% showed cystic change in metastases and almost one-third showed an increase in the size of
metastases during chemotherapy.
The data suggest that post-chemotherapy surgery may have a therapeutic as well as a diagnostic role and
that complete excision of residual disease should be attempted even if resection at one site has shown either
fibrosis or differentiated teratoma. The significance of these findings in relation to treatment induced
differentiation is discussed.
Non-seminomatous germ-cell testicular tumours are
unusual amongst chemocurable human tumours in
that even when chemotherapy has eliminated the
malignant cell population bulky residual masses
may persist. The only certain way of establishing
their histological nature is surgical excision which
may reveal fibrosis and/or necrosis, residual cancer
or differentiated (mature) teratoma. It is the
purpose of the present communication to report
our experience in 73 patients from whom residual
masses were excised after chemotherapy and to
describe their subsequent fate. The findings have
been analysed to understand more fully the
prognostic significance of the histology of resected
tissue, the completeness or otherwise of surgery and
serum marker status prior to chemotherapy and at
the time of surgery. In addition the clinical data
have been examined to see whether there is any
evidence of drug-induced tumour differentiation.
Patients and methods
Patients
Between January 1976 and June 1983, 307 patients
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with advanced non-seminomatous germ-cell
testicular tumours were treated with chemotherapy.
Of this group of 73 (23.8%) had residual masses
excised after treatment.
Stagingprocedure and classification
The Royal Marsden Hospital staging classification
(Peckham, 1981) was employed:
Stage I
Stage IM
Stage II
IIA
IIB
IIC
No metastases evident outside testis
No clinical evidence of metastases
but persistent elevation of serum
AFP and/or beta HCG levels after
orchidectomy
Infra-diaphragmatic nodal
metastases
Metastases <2cm diameter
Metastases 2-5cm diameter
Metastases >5cm diameter
Stage III Supra-diaphragmatic nodal
metastases
Abdominal
status 0=
Stage IV
IVL1
negative lymphogram, A, B, C, as
for Stage II
Extranodal metastases
Pulmonary metastases <3 in
number
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IVL2 Multiple small pulmonary
metastases <2cm diameter
IVL3 Multiple pulmonary metastases One
or more >2cm diameter
IVH + Hepatic involvement
Abdominal status as for Stage II
Treatment protocols
These have been described elsewhere and will only
be summarized here (Peckham et al., 1981, 1983).
Between 1976 and 1978 chemotherapy consisted of
vinblastine and bleomycin (Samuels et al., 1976).
Cis-platinum, vinblastine and bleomycin (Einhorn
& Donohue, 1977) was employed between 1978 and
1980. In selected patients who had had prior
irradiation VP 16-213 (etoposide) was used instead
of vinblastine after 1979 and the combination,
(bleomycin, etoposide and cis-platin [BEP]) used as
first line chemotherapy after 1980 (Peckham et al.,
1983). Selected patients had involved field
irradiation after chemotherapy and prior to surgery
between 1976 and 1981 (Duchesne & Peckham,
1984). All patients were reassessed after four cycles
of chemotherapy with repeat CT scans and serum
marker assay. Patients then proceeded to
radiotherapy and/or surgery or received two further
cycles of chemotherapy before local treatment
methods were employed (Peckham et al., 1981). In
most patients 4-6 weeks elapsed between
completion of chemotherapy and surgery. Apart
from a limited number of patients with small
residual masses who received post chemotherapy
irradiation prior to 1981 and who did not come to
surgery, our policy has been to consider all patients
with residual disease for surgery after
chemotherapy. Post surgical radiotherapy was not
employed.
Pathology
A histological diagnosis of germ-cell malignancy
was verified in all cases and classified as follows:
Malignant teratoma undifferentiated (MTU)
(embryonal carcinoma)
Malignant teratoma intermediate (MTI)
(teratocarcinoma)
Malignant teratoma trophoblastic (MTT)
Teratoma differentiated (TD)
Yolk sac carcinoma (YS)
Associated seminoma components were noted but
did not modify the classification. Seminoma
associated with a raised serum alphafetoprotein
level (serum AFP) was regarded as a non-
seminomatous germ-cell tumour.
Surgery
In most cases (51 patients) surgery involved the
excision of residual disease from the abdomen; 13
patients underwent thoracotomy for excision of
residual pulmonary metastases and/or mediastinal
nodes. Nine patients underwent simultaneous
thoraco-abdominal surgery in order to remove
residual tumour above and below the diaphragm.
Earlier surgical data have been reported (Hendry et
al., 1980). A subsequent report will deal with
surgical details including complications. In the
present series incomplete excision indicates that
residual tumour was left behind either at the
operative site or elsewhere. A difficult excision
indicated an infiltrative mass where excision
although apparently complete was accomplished
with difficulty.
Results
Histology ofresected masses
Of the total of 73 patients 22% had histological
evidence of residual tumour, 44% differentiated
(mature) teratoma and 34% fibrosis and/or
necrosis.
Histology ofprimary tumour in relation to histology
ofrestricted masses after chemotherapy (Table 1)
The majority of patients (75%) who showed
differentiated teratoma in residual masses had MTI
primary tumours. The converse was true in the
group with fibrosis and necrosis where 60% had
MTU primary tumours.
Table I Histology of masses resected after chemotherapy
for advanced testicular non-seminoma in relation to the
histology of the primary tumour (The Royal Marsden
Hospital, 1976-1982)
Histology of Histology ofprimary
ofresected tumour: % distribution
tissues after
chemotherapy MTI MTU MTT Sem AFP+
Malignant tissue (16)a 56 38 6
Differentiated
teratoma (32) 75 19 6
Fibrosis/necrosis (25) 24 60 12 4
aNo. of patients.
Histological evidence ofresidual malignancy
Of a total of 16 patients in this group only 7 (44%)
are alive and disease-free (Table II). Of 4 men who
did not receive chemotherapy after surgery only
one is alive compared with 6/12 patients who were
treated. As discussed below a raised serum marker
level at the time of surgery was an adversePOST-CHEMOTHERAPY SURGERY IN ADVANCED TESTICULAR CANCER 603
Table II Outcome of patients with residual malignant
tissue in masses resected after chemotherapy for non-
seminoma: influence of post-surgical chemotherapy (The
Royal Marsden Hospital, 1976-1982)
Post-surgery No. of Disease- Alive with Dead of
chemotherapy patients free disease tumour
Yes 12 6 (50%) 3 3
No 4 1(25%) 0 3
Total 16 7 (44%)8 3 (19%) 6 (38%)
'Observation time since surgery: 6-78 months (median
23 months).
prognostic feature with only 1/9 patients alive and
disease-free (see Table VI and Figure 3).
Fibrosis and necrosis in residual masses
As shown in Table III of 25 patients in this group
21 (84%) are alive and disease-free. Three patients
had only part of their residual disease excised and
all 3 relapsed. There was one post-operative death
from secondary haemorrhage after abdominal
surgery. Thus, none of the 21 patients who had
residual masses completely excised and who are
available for study have relapsed. Only one patient
had a raised marker at the time of surgery (see
below) and he relapsed having had an incomplete
excision of residual disease.
Table III Resected masses after chemotherapy for
advanced testicular non-seminoma: outcome after surgery
of patients with fibrosis and/or necrosis (The Royal
Marsden Hospital, 1976-1982)
Post-
Total Continuously Alive with Dead of operative
patients disease-free disease tumour death
25c 21 (84%) 2b la 1
aIncomplete surgery subsequent biopsy showed MTU.
bOne patient had incomplete surgery and has residual
static disease present. The second has incomplete surgery
and has relapsed.
cObservation time 8-87 months (median 40 months).
Table IV Non-seminomatous germ-cell testicular
tumours: outcome of patients with mature (differentiated)
teratoma in masses resected after chemotherapy in
relation to completeness of surgery (The Royal Marsden
Hospital 1976-1982)
Total Continuously
Extent ofsurgery patients disease-free Relapsed
Complete
resection 23 22 (96%) 1 (4%)
Resected with
difficulty 5 4 (80%) 1 (20%)
Incomplete 4 1 (25%) 3 (75%)
Total 32a 27 (84%) 5 (16%)
aObservation time 13-68 months (median 37 months).
Differentiated (mature teratoma) in resected masses
(Table IV)
The most commonly reported tissues present in
masses characterized as differentiated teratoma
were squamous, respiratory or columnar
epithelium, smooth muscle, cartilage, neural tissue,
adipose and connective tissue. As discussed below
cystic change was very common.
Although the overall prognosis of patients who
show differentiated teratoma in resected masses is
good, with 84% surviving disease-free (observation
time 13-68 months, median 37 months), relapses
may occur with risk being related to the
completeness or otherwise of surgery as shown in
Table IV. Thus whereas only 1/23 patients in whom
a complete excision had been performed relapsed,
4/9 men where excision had either been
accomplished with difficulty or been incomplete
subsequently relapsed. Of the latter group one has
died of tumour (27 months after surgery), two are
alive with active disease (11 & 41 months) and one
is alive with static disease (56 months). The patient
who relapsed after an apparently complete excision
showed raised markers as the only evidence of
relapse and is disease-free after further
chemotherapy at 36 months.
As shown in Table V cystic change was
documented in 88% of masses showing
Table V Differentiated teratoma (TD) in masses resected after
chemotherapy for non-seminomatous germ-cell testicular tumours: cystic
change and enlargement during treatment (The Royal Marsden Hospital,
1976-1982)
Totalpatients Cystic Increase in volume Appearance ofmass
with TD in change ofmass observed de novo during
surgical specimen present during chemotherapy chemotherapy
32 28 (88%) 10 (31%) 1 (3%)604 D. TAIT et al.
differentiated teratoma. Almost one-third of
patients showed an increase in size of mass during
chemotherapy and in one patient a cystic mass
appeared although clinical staging had failed to
reveal evidence of tumour at that site prior to
chemotherapy. Enlargement of cystic masses during
or after chemotherapy may produce symptoms and
necessitate early surgery. In one patient in the
present series bilateral ureteric obstruction occurred
and it was necessary to drain cyst fluid by
percutaneous needle aspiration.
Figure 1 shows the growth pattern in two
pulmonary metastases in the patient designated as
having static disease after the excision (with
difficulty) of a retroperitoneal mass of differentiated
teratoma. Numerous bilateral lung metastases
appeared within one month of surgery the patient
never having shown evidence of lung disease
previously. Following initially rapid tumour growth
most metastases have remained static, some
showing very slow expansion over several years.
Serum markers, surgicalpathology andsubsequent
outcome
Figure 2 shows serum marker levels prior to
chemotherapy in relation to the histology of
resected masses. There is no obvious difference in
the distribution of patients with low and high
marker levels in the three histological subgroups.
Figure 3 shows pre-surgical marker status in
relation to eventual outcome in patients with
histological evidence of residual malignancy in the
resected specimen. As shown there is a high risk of
relapse in patients with raised markers. In patients
who were marker positive immediately before
surgery the prognosis is poor even when post-
surgical chemotherapy is given (Table VI). However
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Figure 1 Rapid appearance and subsequent growth pattern of pulmonary metastases resection of a residual
abdominal mass showing mature teratoma after chemotherapy for Stage IIC testicular non-seminoma.
Table VI Patients with residual malignant tissue in masses resected after
chemotherapy for advanced testicular non-seminoma: serum marker status
and subsequent chemotherapy (The Royal Marsden Hospital, 1976-1982)
Serum marker
status at time Post-surgical Number of Disease- Alive with Dead of
ofsurgery chemotherapy patients free disease tumour
Marker positive YES 6 1 2 3
patients (9)' NO 3 3
Marker negative YES 6 5 1
patients (7) NO 1 1
aNo. ofpatients ( ).
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Figure 2 Surgery after chemotherapy for advanced testicular non-seminoma: Surgical pathology in relation
to pre-chemotherapy serum marker status.
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Figure 3 Post-chemotherapy excision of residual masses in testicular non-seminoma: influence of serum
marker status at time of surgery on disease outcome in patients with evidence of residual malignancy in
resected tissue.606 D. TAIT et al.
in most cases surgery was performed in the marker
positive patient because the possibilities of first line
chemotherapy had been exhausted and only second
line chemotherapy was possible after resection of
the residual mass.
In the group with differentiated teratoma in the
surgical specimen only one patient had raised serum
markers (AFP 18ngml-1 and HCG 14iul-1) prior
to surgery and this patient relapsed and is receiving
further chemotherapy.
In the fibrosis/necrosis group only one man had
a raised marker prior to surgery (HCG 16iu - 1)
and he relapsed. However surgery was incomplete
and at a second exploration residual MTU was
confirmed.
Of the total of 17 relapsed patients abdominal
recurrence occurred in seven (all with prior C
disease), lungs in three (only one of whom had had
lung metastases initially), lungs and abdomen in
three (only one of whom had lung metastases
initially), elevation of serum markers in one and
extradural cord compression in one patient.
Discussion
The present results confirm that the patients most
at risk from relapse following resection of masses
after chemotherapy for testicular cancer are those
in whom there is histological evidence of residual
malignancy in the surgical specimen, Such patients
have a poor prognosis unless further chemotherapy
is given. Marker status at the time of surgery,
completeness or otherwise of resection and post
surgical chemotherapy all influence the survival
prospects of the patient. Bracken et al. (1983)
reported that 9/17 patients who had residual
malignant tissue resected and who were marker
negative at the time of surgery were salvaged by
further chemotherapy ± surgery. Vugrin et al.
(1981) reported that of 11 marker negative patients
who had complete resection of a residual mass
showing histological evidence of malignancy nine
were disease-free 5-33 months after surgery. The
need for further chemotherapy after resection of
active tumour is illustrated by the experience of
Einhorn et al. (1981) who found that only 2/22
patients with resected carcinoma were continuously
disease-free after surgery.
In patients with histological evidence of residual
malignancy, those with raised serum markers at the
time of surgery (that is after chemotherapy), even if
there is only a slight elevation of one marker, are
most at risk of relapse although if a complete
resection can be achieved and there is scope for
giving further effective chemotherapy the patient
may be salvaged. Patients who are marker negative
and who show focal residual malignant tissue
within the surgical specimen have fared best,
although even in this group further chemotherapy
appears necessary. It is difficult from limited data
to dissociate the diagnostic and therapeutic roles of
surgery in patients with evidence of residual
malignancy. However, the observation that the
patients most at risk are those who do not have a
complete resection, suggest that surgery contributes
to cure by removing all macroscopically evident
tumour. Support for the therapeutic contribution of
surgery also comes from our limited historical
experience where long term disease-free survival
was achieved in patients from whom masses were
excised after ineffective chemotherapy +
radiotherapy prior to 1975 (Hendry et al., 1980).
The histological appearances of residual masses
may be heterogeneous with an admixture of
fibrosis, mature teratoma and residual malignant
tissue. Thus, resection of part of a residual mass or
only some of the metastases remaining after
chemotherapy may predispose to relapse even in
marker negative patients who do not have elevated
serum markers after chemotherapy and prior to
surgery and who show the histological appearances
of fibrosis with necrosis or mature teratoma in the
surgical specimen. Donohue et al. (1982) reporting
on 51 patients who came to surgery after
chemotherapy found that 16 (31%) showed fibrosis
with necrosis, 16 (31%) mature teratoma and 19
(37%) residual cancer. In the fibrosis/necrosis
group 2/16 patients who did not have complete
resection subsequently relapsed. In a more recent
report from the same group, of 54 patients who
had teratomatous masses excised after
chemotherapy (16 (30%) relapsed (Loehrer et al.,
1983). This included 41 patients with mature
teratoma of whom 11 (29%) relapsed and 13
patients described as showing the appearances of
immature teratoma of whom 5 (38%) had relapsed.
A major factor predisposing to relapse was the
completeness of surgical resection.
In some patients the subsequent spread pattern
after surgery, when the histology is positive,
suggests that haematogenous spread may occur at
the time of resection. In patients with Stage II
disease, in whom it is suspected that there may be
residual malignancy present within the abdominal
mass and in whom there is little in the way of
chemotherapy reserve, the possible contribution of
involved field irradiation should not be ignored
(Duchesne & Peckham, 1984).
The presence of raised serum markers prior to
surgery and after chemotherapy is associated with
the histological findings of residual malignancy.
Conversely negative markers do not predict the
absence of a positive histology. This Vugrin et al.
(1981) reporting on 47 patients operated upon after
chemotherapy found that 8/9 marker positivePOST-CHEMOTHERAPY SURGERY IN ADVANCED TESTICULAR CANCER 607
patients had residual cancer whereas of 38 marker
negative patients 11 (29%) had malignant tissue,
9 (24%) mature teratoma and 18 (47%)
fibrosis/necrosis. Bracken et al. (1983) submitted 60
patients, all of whom had normal serum markers,
to surgery after chemotherapy. Of this group 22
were judged to be in complete clinical remission
after chemotherapy yet 5 (23%) had residual
malignancy, 3 (14%) mature teratoma and 14 (64%)
fibrosis/necrosis. In 38 marker negative patients
with residual masses, 12 (32%) showed active
tumour and 11 (29%) mature teratoma.
In patients with fibrosis and necrosis in the
histological specimen the prognosis is good, only
three failures have been seen, all in patients in
whom there was incomplete excision of all disease
and where relapse appeared in unresected tumour
masses. These observations underline the fact that
the histology of resected tissue in one site does not
necessarily reflect that at other sites and that if
possible an attempt should be made to excise all
residual tumour after chemotherapy.
Perhaps the most fascinating group are those
exhibiting histological evidence of differentiated
teratoma. Differentiated teratoma may contain
connective tissue, cartilage, smooth muscle, bone,
nervous tissue, mucus secreting epithelium,
squamous epithelium, ciliated epithelium and fat.
Brodner et al. (1980) have described endocrine cells
in 11/53 testicular teratomas associated with
gastrointestinal epithelium. Most frequent were
enterochromaffin cells but somatostatin, glucogen
and pancreatic polypeptide immunoreactive cells
were also identified. Bosman & Louwerens (1981)
have also reported intestinal types of APUD cells in
testicular teratoma.
In this series differentiated teratoma constituted
44% of patients who came to surgery and the
overall prognosis is good. However, as with the
previous two groups the completeness otherwise of
surgery exerts an influence on subsequent outcome.
Patients who have had a complete excision of
residual masses and in whom there is only evidence
of mature teratoma, have ahi excellent prognosis
and no further treatment is required. The data are
more limited for patients in whom surgery was
difficult because of densely adherent tumour or
where there was incomplete removal of residual
disease. In both categories, however, the patient is
at higher risk of relapse. In those patients where
there has been resection only of part of the disease
process, a subsequent attempt should be made to
resect masses at all sites.
In practical terms patients with cystic
differentiated teratoma may present a formidable
problem in management, since surgery may be
required for bulky cervical disease, intra-thoracic
disease and masses in the abdomen and pelvis.
Enlargement of masses may in itself be an
indication for surgery because of the risk of airways
compression, ureteric obstruction, etc. In such
patients chemotherapy may be interrupted and the
inter-digitation of systemic treatment and surgery
may be intricate. Enlargement of cystic masses may
be attributed to tumour growth and failure of
chemotherapy if the evolution of expanding cystic
differentiated teratoma is not taken into
consideration (Logothetis et al., 1982; Carr et al.,
1981). In some patients teratoma cyst fluid may
contain high levels of AFP and/or HCG and this
may be a guide to whether residual malignancy is
present or not, and if so, which mass should be
tackled as a surgical priority.
The phenomenon of differentiation in testicular
malignancy is of great interest. Regression with
spontaneous maturation of primary testicular
tumours is a rare but well documented
phenomenon. Azzopardi et al. (1961) reporting 17
patients who died of widespread germ-cell
malignancy in whom no testicular primary was
clinically evident found intratesticular cystic lesions
in eight cases. This syndrome is often associated
with trophoblastic malignancy and rapidly
progressive disease carrying a poor prognosis
(Powell et al., 1983). The phenomenon of change
towards a more benign state in metastases from
testicular germ-cell tumours has long been
recognised (Smithers, 1969). Numerous reports
describe differentiated teratoma metastases excised
after chemotherapy and/or radiotherapy (Duari,
1967; Willis & Hajdu, 1973; Merrin et al., 1975;
Stechmiller et al., 1976; Hong et al., 1977; Hendry
et al., 1980; Einhorn et al., 1981; Vugrin et al.,
1981; Stahel et al., 1982; Bracken et al., 1983;
Callery et al., 1983; Oosterhuis et al., 1983; van
Dongen et al., 1983). Whereas prior to the recent
developments in chemotherapy this evolution
towards morphological differentiation was
uncommon it is now a well recognised feature.
An intriguing question is whether differentiation
is promoted by treatment or whether chemotherapy
eradicates undifferentiated elements leaving pre-
existing differentiated structures in situ. Oosterhuis
et al. (1982) have used mouse teratocarcinoma as a
model for human testicular cancer to investigate the
effects of cis-platin on differentiation and concluded
that chemotherapy eradicates undifferentiated
tumour leaving differentiated elements rather than
promoting differentiation.
In the present series 75% of patients in whom
differentiated masses were excised had intermediate
malignant teratoma primary tumours, that is with
evidence of differentiation present. As shown in
Figure 4 radical lymph node dissection data from
the prechemotherapy era indicate that the presence
of differentiated elements in the primary tumour
predisposes to some degree of differentiation in
metastases. Even with earlier forms of therapy608 D. TAIT et al.
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Figure 4 Histology of resected abdominal nodes in
relation to histology ofprimary testicular tumour (Data
taken from Ray et al., 1974). (E) Primary tumour:
non-seminoma with no differentiated elements (total
74). (3) Primary tumour: non-seminoma with
differentiated elements (total 46).
(radiotherapy and single agent chemotherapy)
completely differentiated masses were encountered.
This in our own experience of 13 (highly selected)
patients operated upon between 1968 and 1976 for
bulky residual disease four (30%) had fully
differentiated residua (Hendry et al., 1980). Recent
data for Oosterhuis et al. (1983) demonstrate that
there has been a progressive increase in the
proportion of patients showing differentiated
teratoma metastases as chemotherapy has become
more effective; this increase is largely confined to
patients who have differentiated elements in the
primary tumour.
Induction of complete differentiation leading to
fully mature end cells has obvious attraction as a
therapeutic manoeuvre in germ-cell malignancy.
The question arises as to whether there is evidence
that the chemotherapy that has proved so effective
in curing this once lethal disease acts at least in
part by inducing differentiation. On presently
available evidence it is not possible to exclude the
possibility that differentiation is treatment-induced
although the data can equally well be interpreted to
indicate that chemotherapy has eradicated
undifferentiated tumour leaving pre-existing
differentiated elements in situ.
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